Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Ivacaftor
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]